for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BB BIOTECH AG

BION.S

Latest Trade

65.20CHF

Change

-0.10(-0.15%)

Volume

48,873

Today's Range

64.95

 - 

65.75

52 Week Range

55.05

 - 

73.65

As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
65.30
Open
65.70
Volume
48,873
3M AVG Volume
1.75
Today's High
65.75
Today's Low
64.95
52 Week High
73.65
52 Week Low
55.05
Shares Out (MIL)
55.40
Market Cap (MIL)
3,617.62
Forward P/E
11.95
Dividend (Yield %)
5.05

Next Event

BB Biotech AG at Edison Non Deal Roadshow - Scotland

Latest Developments

More

BB Biotech Q3 Net Loss At CHF 382 Mln

BB Biotech Sees Portfolio Cos To Report Q4 Pipeline Progress

BB Biotech H1 Net Profit At CHF 554 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About BB BIOTECH AG

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.

Industry

Misc. Financial Services

Contact Info

Schwertstrasse 6

+41.52.6240845

https://www.bbbiotech.ch/

Executive Leadership

Erich Hunziker

Chairman of the Board

Clive A. Meanwell

Vice Chairman of the Board of Directors

Michael Hutter

Chief Financial Officer, Chief Compliance Officer

Rudy Le Blanc

Board Member and Managing Director of the BB Biotech Branch Office in Curacao

Tanja Chicherio

Marketing & Communication Officer

Key Stats

2.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, CHF)

2016

0.0K

2017

0.7K

2018

0.0K

2019(E)

0.2K
EPS (CHF)

2016

-14.510

2017

12.420

2018

-8.510

2019(E)

5.463
Price To Earnings (TTM)
--
Price To Sales (TTM)
618.71
Price To Book (MRQ)
1.25
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
11.77
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-14.67
Return on Equity (TTM)
-13.27

Latest News

Latest News

BRIEF-BB Biotech Sees Portfolio Cos To Report Q4 Pipeline Progress

* EXPECTS PORTFOLIO COMPANIES TO REPORT SUBSTANTIAL PIPELINE PROGRESS DURING Q4 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-BB Biotech Q3 Net Loss At CHF 382 Mln

* NET PROFIT FOR PERIOD ENDED SEPTEMBER 30, 2019 AMOUNTED TO CHF 172 MN (PROFIT OF CHF 172 MN IN SAME PERIOD 2018)

BRIEF-BB Biotech H1 Net Profit At CHF 554 Mln

* CONSOLIDATION LEAVES A MARK ON RESULTS IN THE SECOND QUARTER

BRIEF-BB Biotech Q1 Profit Of CHF 890 Million

* Q1 PROFIT OF CHF 890 MN (PROFIT OF CHF 28 MN IN CORRESPONDING PERIOD OF PREVIOUS YEAR) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-BB Biotech Launches New Buyback Program

* SAID ON THURSDAY CONCLUDES ITS SHARE BUYBACK PROGRAM AND LAUNCHES A NEW BUYBACK PROGRAM

BRIEF-BB Biotech FY Net Result Swings To Loss Of CHF 471 Million

* FY NET LOSS OF CHF 471 MN COMPARED TO A NET GAIN OF CHF 688 MN FOR FULL YEAR OF 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-BB Biotech FY Net Result Swings To Loss Of CHF 471 Million

* BB BIOTECH INVESTS GAINS OF M&A TRANSACTIONS IN NEW TECHNOLOGIES - DIVIDEND OF CHF 3.05 PROPOSED

BRIEF-BB Biotech Enlarges Its Board Of Directors

* WILL PROPOSE DR. THOMAS VON PLANTA FOR ELECTION TO ITS BOARD OF DIRECTORS.

BRIEF-BB Biotech Q3 Net Gain Up At CHF 242 Mln

* DGAP-NEWS: BB BIOTECH AG: INVESTORS SHOWED RENEWED INTEREST IN BIOTECH STOCKS DURING THE THIRD QUARTER

BRIEF-BB Biotech Q3 Profit Down At CHF 242 Mln

* FOR NINE MONTHS PERIOD ENDED SEPTEMBER 30, 2018 A PROFIT OF CHF 172 MILLION VERSUS CHF 843 MILLION YEAR AGO

BRIEF-BB Biotech Q2 Net Result Swings To Loss Of CHF 98 Mln

* Q2 NET LOSS OF CHF 98 MN. VERSUS NET PROFIT OF CHF 103 MN REPORTED FOR Q2 OF 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-BB Biotech H1 Loss At Around CHF 70 Mln

* H1 LOSS OF AROUND CHF 70 MLN (CHF 478.4 MLN PROFIT IN CORRESPONDING PERIOD OF PREVIOUS YEAR) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-BB Biotech Q1 Profit Of CHF 28 Mln

* DGAP-ADHOC: BB BIOTECH SHARE GAINS VALUE IN FIRST QUARTER 2018 - SEVERAL LARGE-CAP BIOTECH COMPANIES TRADING AT WELL BELOW FUNDAMENTAL VALUE

BRIEF-BB Biotech FY Net Result Turns to Profit Of CHF 688 Million

* FY NET GAIN OF CHF 688 MN COMPARED TO A NET LOSS OF CHF 802 MN IN PREVIOUS PERIOD

BRIEF-BB Biotech to propose 3.30 Sfr dividend for 2017

* SHOWS A DOUBLE-DIGIT TOTAL RETURN FOR 2017 - MID CAPS OVERDELIVER ON INNOVATION AND ARE BECOMING A KEY UPSIDE TRIGGER

BRIEF-BB Biotech Reports 5.6% Passive Stake In Voyager Therapeutics

* BB BIOTECH AG REPORTS 5.6% PASSIVE STAKE IN VOYAGER THERAPEUTICS AS OF JAN 3 - SEC FILING Source text: (http://bit.ly/2CZEeZD) Further company coverage:

BRIEF-BB Biotech Q3 net profit down at CHF 365 million

* PRODUCT APPROVALS AND SOLID COMPANY RESULTS LEAD THE BIOTECH SECTOR HIGHER

BRIEF-BB Biotech reports 5.1 pct passive stake in Intra-Cellular Therapies

* BB Biotech AG reports 5.1 percent passive stake in Intra-Cellular Therapies Inc as of August 18, 2017 - SEC filing Source text: (http://bit.ly/2xcLrz4) Further company coverage:

BRIEF-BB Biotech H1 net result turns to profit of CHF 478 mln

* CONSEQUENTLY, H1 2017 NET INCOME AMOUNTED TO CHF 478 MN, COMPARED TO A LOSS OF CHF 1 170 MN FOR H1 2016

BRIEF-BB Biotech posts Q1 net profit of 375 million Swiss francs

* Earned a bottom-line profit of 375 million Swiss francs ($375.45 million) in Q1 of 2017

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up